DK1476162T3 - Kontrolleret syntese af ziprasidone - Google Patents

Kontrolleret syntese af ziprasidone

Info

Publication number: DK1476162T3
Authority: DK; Denmark
Prior art keywords: ziprasidone; controlled synthesis; synthesis; controlled
Prior art date: 2002-02-20

Application number

DK03702918T

Other languages

English (en)

Inventor

Adam Worth Grobin

Frank Robert Busch

Harry Ralph Howard Jr

Kyle Robert Leeman

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-20

Filing date

2003-02-17

Publication date

2007-07-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1476162(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-17 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2007-07-02 Application granted granted Critical

2007-07-02 Publication of DK1476162T3 publication Critical patent/DK1476162T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Liquid Crystal Substances (AREA)
Indole Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Plural Heterocyclic Compounds (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Pyridine Compounds (AREA)

DK03702918T 2002-02-20 2003-02-17 Kontrolleret syntese af ziprasidone DK1476162T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US35880602P	2002-02-20	2002-02-20
US35903802P	2002-02-21	2002-02-21
US36045902P	2002-02-27	2002-02-27
PCT/IB2003/000642 WO2003070246A1 (en)	2002-02-20	2003-02-17	Controlled synthesis of ziprasidone and compositions thereof

Publications (1)

Publication Number	Publication Date
DK1476162T3 true DK1476162T3 (da)	2007-07-02

Family

ID=27761437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03702918T DK1476162T3 (da)	2002-02-20	2003-02-17	Kontrolleret syntese af ziprasidone

Country Status (41)

Country	Link
EP (1)	EP1476162B1 (da)
JP (1)	JP4554938B2 (da)
KR (1)	KR100773622B1 (da)
CN (2)	CN101735212A (da)
AP (1)	AP2004003103A0 (da)
AR (1)	AR038563A1 (da)
AT (1)	ATE359787T1 (da)
AU (2)	AU2003206035A1 (da)
BR (1)	BR0307833A (da)
CA (1)	CA2475302C (da)
CO (1)	CO5611138A2 (da)
CY (1)	CY1106467T1 (da)
DE (1)	DE60313289T2 (da)
DK (1)	DK1476162T3 (da)
EA (1)	EA007866B1 (da)
EC (1)	ECSP045239A (da)
ES (1)	ES2283745T3 (da)
GE (1)	GEP20074030B (da)
GT (1)	GT200300040A (da)
HR (1)	HRP20040711A2 (da)
IL (1)	IL163277A (da)
IS (1)	IS7344A (da)
MA (1)	MA27177A1 (da)
MX (1)	MXPA04006993A (da)
MY (1)	MY139523A (da)
NO (2)	NO20043902L (da)
NZ (1)	NZ534443A (da)
OA (1)	OA12774A (da)
PA (1)	PA8567001A1 (da)
PE (1)	PE20030942A1 (da)
PL (1)	PL372238A1 (da)
PT (1)	PT1476162E (da)
RS (1)	RS60404A (da)
SI (1)	SI1476162T1 (da)
SV (1)	SV2004001485A (da)
TN (1)	TNSN04159A1 (da)
TW (1)	TW200307546A (da)
UA (1)	UA77057C2 (da)
UY (1)	UY27668A1 (da)
WO (1)	WO2003070246A1 (da)
ZA (1)	ZA200406276B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100879647B1 (ko)	2000-03-06	2009-01-20	아카디아 파마슈티칼스 인코포레이티드	세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
NZ533567A (en)	2001-12-28	2007-06-29	Acadia Pharm Inc	Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
US7538222B2 (en)	2002-06-24	2009-05-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en)	2002-06-24	2007-08-07	Carl-Magnus Andersson	N-substituted piperidine derivatives as serotonin receptor agents
JP2005533813A (ja)	2002-06-24	2005-11-10	アカディアファーマシューティカルズ，インコーポレーテッド	セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体
US7488729B2 (en)	2002-12-04	2009-02-10	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) *	2002-12-04	2004-06-17	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride
ATE407117T1 (de)	2003-01-16	2008-09-15	Acadia Pharm Inc	Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
US7199144B2 (en)	2003-04-21	2007-04-03	Teva Pharmaceuticals Industries, Ltd.	Process for the preparation of valsartan and intermediates thereof
DE602004013405T2 (de)	2003-03-17	2009-05-07	Teva Pharmaceutical Industries Ltd.	Polymorphe formen von valsartan
EP1618097A1 (en)	2003-04-21	2006-01-25	Teva Pharmaceutical Industries Ltd	Process for the preparation of valsartan
US7678799B2 (en)	2003-06-03	2010-03-16	Teva Pharmaceutical Industries Ltd.	Crystalline ziprasidone HCl and processes for preparation thereof
CA2543805A1 (en)	2003-10-24	2005-05-06	Gideon Pilarsky	Processes for preparation of ziprasidone
JP2007514001A (ja) *	2003-12-18	2007-05-31	テバファーマシューティカルインダストリーズリミティド	ジプラシドン塩基の多形形態ｂ２
ATE451367T1 (de) *	2004-02-27	2009-12-15	Ranbaxy Lab Ltd	Verfahren zur herstellung von ziprasidon
CA2467538C (en)	2004-05-14	2010-08-24	Apotex Pharmachem Inc.	New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en)	2004-05-21	2010-10-26	Acadia Pharmaceuticals, Inc.	Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en)	2004-06-14	2005-12-14	Apotex Pharmachem Inc.	Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
CN101031548B (zh)	2004-09-27	2011-04-06	阿卡蒂亚药品公司	N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
US7790899B2 (en)	2004-09-27	2010-09-07	Acadia Pharmaceuticals, Inc.	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2250000B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Procedimiento para la preparacion de ziprasidona.
ES2250001B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Proceso para la purificacion de ziprasidona.
WO2006080025A1 (en) *	2005-01-27	2006-08-03	Hetero Drugs Limited	Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) *	2005-11-18	2007-05-19	Dipharma Spa	Procedimento per la preparazione di ziprasidone
CN100491375C (zh) *	2006-07-01	2009-05-27	浙江美诺华药物化学有限公司	一种齐拉西酮的制备方法
WO2008116024A2 (en)	2007-03-19	2008-09-25	Acadia Pharmaceuticals Inc.	Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN102234272A (zh) *	2010-04-21	2011-11-09	上海医药工业研究院	盐酸齐拉西酮半水合物的制备方法
CN102234273B (zh) *	2010-04-21	2015-08-05	上海医药工业研究院	甲磺酸齐拉西酮半水合物及其制备方法
CN107848972B (zh)	2015-07-20	2021-06-18	阿卡蒂亚药品公司	用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法
WO2017165635A1 (en)	2016-03-25	2017-09-28	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en)	2016-03-25	2021-03-23	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en)	2016-12-20	2019-10-30	Acadia Pharmaceuticals Inc.	Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
CN108239085A (zh) *	2016-12-26	2018-07-03	四川科瑞德凯华制药有限公司	一种甲磺酸齐拉西酮的纯化及制备方法
WO2018200977A1 (en)	2017-04-28	2018-11-01	Acadia Pharmaceuticals Inc.	Pimavanserin for treating impulse control disorder
WO2019046167A1 (en)	2017-08-30	2019-03-07	Acadia Pharmaceuticals Inc.	PIMAVANSERIN FORMULATIONS
CN112724066B (zh) *	2021-02-04	2022-10-21	海南鑫开源医药科技有限公司	一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) *	2023-01-17	2023-05-02	北京协和建昊医药技术开发有限责任公司	一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4831031A (en)	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en)	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) *	1992-08-26	1994-08-16	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en) *	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) *	1993-06-28	1994-10-25	Pfizer Inc.	Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DE69611253T2 (de)	1995-11-07	2001-04-05	Pfizer Inc., New York	Verfahren und zwischenprodukte für die herstellung von 3-(1-piperazinyl)-1,2-benzisothiazolen
TR199802241T2 (da) *	1996-05-07	1999-02-22	Pfizer Inc.
TW491847B (en)	1996-05-07	2002-06-21	Pfizer	Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) *	1997-12-18	2002-07-25	Pfizer Prod Inc	Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) *	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations

2003
- 2003-02-14 UY UY27668A patent/UY27668A1/es not_active Application Discontinuation
- 2003-02-17 RS YU60404A patent/RS60404A/sr unknown
- 2003-02-17 KR KR1020047012980A patent/KR100773622B1/ko not_active Expired - Fee Related
- 2003-02-17 AT AT03702918T patent/ATE359787T1/de active
- 2003-02-17 JP JP2003569202A patent/JP4554938B2/ja not_active Expired - Fee Related
- 2003-02-17 SI SI200330811T patent/SI1476162T1/sl unknown
- 2003-02-17 AP APAP/P/2004/003103A patent/AP2004003103A0/en unknown
- 2003-02-17 BR BR0307833-7A patent/BR0307833A/pt not_active IP Right Cessation
- 2003-02-17 UA UA20040806969A patent/UA77057C2/uk unknown
- 2003-02-17 MX MXPA04006993A patent/MXPA04006993A/es not_active Application Discontinuation
- 2003-02-17 NZ NZ534443A patent/NZ534443A/en not_active IP Right Cessation
- 2003-02-17 GE GE5684A patent/GEP20074030B/en unknown
- 2003-02-17 AU AU2003206035A patent/AU2003206035A1/en not_active Abandoned
- 2003-02-17 OA OA1200400216A patent/OA12774A/en unknown
- 2003-02-17 CA CA002475302A patent/CA2475302C/en not_active Expired - Fee Related
- 2003-02-17 ES ES03702918T patent/ES2283745T3/es not_active Expired - Lifetime
- 2003-02-17 CN CN200910261963A patent/CN101735212A/zh active Pending
- 2003-02-17 CN CNA038042460A patent/CN1635892A/zh active Pending
- 2003-02-17 PL PL03372238A patent/PL372238A1/xx not_active Application Discontinuation
- 2003-02-17 DK DK03702918T patent/DK1476162T3/da active
- 2003-02-17 PE PE2003000168A patent/PE20030942A1/es not_active Application Discontinuation
- 2003-02-17 WO PCT/IB2003/000642 patent/WO2003070246A1/en not_active Ceased
- 2003-02-17 EP EP03702918A patent/EP1476162B1/en not_active Revoked
- 2003-02-17 DE DE60313289T patent/DE60313289T2/de not_active Revoked
- 2003-02-17 HR HRP20040711 patent/HRP20040711A2/xx not_active Application Discontinuation
- 2003-02-17 PT PT03702918T patent/PT1476162E/pt unknown
- 2003-02-17 EA EA200400815A patent/EA007866B1/ru not_active IP Right Cessation
- 2003-02-18 TW TW092103292A patent/TW200307546A/zh unknown
- 2003-02-18 AR ARP030100527A patent/AR038563A1/es unknown
- 2003-02-18 GT GT200300040A patent/GT200300040A/es unknown
- 2003-02-18 MY MYPI20030564A patent/MY139523A/en unknown
- 2003-02-19 SV SV2003001485A patent/SV2004001485A/es not_active Application Discontinuation
- 2003-02-20 PA PA20038567001A patent/PA8567001A1/es unknown
2004
- 2004-07-05 IS IS7344A patent/IS7344A/is unknown
- 2004-07-29 IL IL163277A patent/IL163277A/en unknown
- 2004-08-05 ZA ZA200406276A patent/ZA200406276B/en unknown
- 2004-08-13 CO CO04079019A patent/CO5611138A2/es unknown
- 2004-08-17 MA MA27827A patent/MA27177A1/fr unknown
- 2004-08-19 TN TNP2004000159A patent/TNSN04159A1/fr unknown
- 2004-08-19 EC EC2004005239A patent/ECSP045239A/es unknown
- 2004-09-17 NO NO20043902A patent/NO20043902L/no not_active Application Discontinuation
2007
- 2007-05-10 CY CY20071100629T patent/CY1106467T1/el unknown
2009
- 2009-05-21 AU AU2009202008A patent/AU2009202008A1/en not_active Ceased
2010
- 2010-04-22 NO NO20100584A patent/NO20100584L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TW200307546A (en)	2003-12-16
GEP20074030B (en)	2007-02-12
BR0307833A (pt)	2004-12-07
CN101735212A (zh)	2010-06-16
CO5611138A2 (es)	2006-02-28
GT200300040A (es)	2007-01-12
EP1476162A1 (en)	2004-11-17
PE20030942A1 (es)	2003-11-08
MXPA04006993A (es)	2004-11-10
PT1476162E (pt)	2007-06-25
CA2475302C (en)	2009-05-12
EA007866B1 (ru)	2007-02-27
CN1635892A (zh)	2005-07-06
NZ534443A (en)	2007-07-27
IL163277A (en)	2010-05-31
ECSP045239A (es)	2004-09-28
NO20043902L (no)	2004-09-17
EP1476162B1 (en)	2007-04-18
MY139523A (en)	2009-10-30
CY1106467T1 (el)	2012-01-25
TNSN04159A1 (fr)	2007-03-12
NO20100584L (no)	2004-09-17
SI1476162T1 (sl)	2007-08-31
JP4554938B2 (ja)	2010-09-29
DE60313289T2 (de)	2007-12-27
CA2475302A1 (en)	2003-08-28
KR20040086417A (ko)	2004-10-08
UY27668A1 (es)	2003-10-31
AU2009202008A1 (en)	2009-06-11
ES2283745T3 (es)	2007-11-01
DE60313289D1 (de)	2007-05-31
RS60404A (sr)	2006-10-27
KR100773622B1 (ko)	2007-11-05
JP2005525347A (ja)	2005-08-25
PL372238A1 (en)	2005-07-11
PA8567001A1 (es)	2003-12-10
EA200400815A1 (ru)	2004-12-30
AP2004003103A0 (en)	2004-09-30
HRP20040711A2 (en)	2004-12-31
WO2003070246A1 (en)	2003-08-28
AR038563A1 (es)	2005-01-19
IS7344A (is)	2004-07-05
ZA200406276B (en)	2005-09-20
SV2004001485A (es)	2004-05-07
ATE359787T1 (de)	2007-05-15
UA77057C2 (en)	2006-10-16
AU2003206035A1 (en)	2003-09-09
OA12774A (en)	2006-07-04
MA27177A1 (fr)	2005-01-03

Publication	Publication Date	Title
IS7344A (is)	2004-07-05	Stýrð efnasmíði síprasídóns og samsetninga af því
DK1778618T3 (da)	2014-03-10	Syntese af triethylentetraminer
IL230659A (en)	2016-02-29	Calicheamicin derivative-carrier conjugates
DK1438306T3 (da)	2014-06-23	Derivater af UK-2A
DK1802579T3 (da)	2014-01-20	Derivater af 3-arylaminopyridin
SI1897548T2 (sl)	2024-09-30	Regulacija celic T
DK1658295T3 (da)	2007-09-24	Regioselektiv syntese af CCI-779
IS7007A (is)	2003-10-30	Kristallaform af asiþrómýsíni
DK1360169T3 (da)	2007-11-26	Succinatsalt af O-desmethyl-venlafaxin
DK2377869T3 (da)	2014-04-14	Syntese af Bortezomib
DK1587542T3 (da)	2012-07-30	Anvendelse af anti-CD100-antistoffer
DK1803718T3 (da)	2008-10-27	4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1470732T3 (da)	2019-12-02	Fremskaffelse af lokaliseringsinformation
DK1663991T3 (da)	2007-04-10	Selektiv syntese af CF3-substituerede pyrimidiner
DK1516540T3 (da)	2012-11-26	Anvendelse af vitamin D-forbindelser
ATE364610T1 (de)	2007-07-15	Kristalline polymorphe form von irinotecan- hyrochlorid
DE502004011575D1 (de)	2010-10-07	Verwendung von Dioldimerfettsäureestern
ATE356124T1 (de)	2007-03-15	Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7- one
DE50302584D1 (de)	2006-05-04	Stereomikroskop
DE50302514D1 (de)	2006-04-27	Stereomikroskop
DK1578774T3 (da)	2014-02-03	Oprensning af immunoglobuliner
IS7833A (is)	2005-05-02	Efnasambönd með sameinaða heteróhringi
DE60332980D1 (de)	2010-07-29	Sprachsynthese
DK1565563T3 (da)	2013-01-21	Enzymatisk syntese af polyolacrylater
DK1567524T3 (da)	2009-11-16	Thia-epothilonderivater til behandling af cancer